Upcoming Dividend • May 12
Upcoming dividend of €3.64 per share Eligible shareholders must have bought the stock before 19 May 2026. Payment date: 21 May 2026. Trailing yield: 6.2%. Within top quartile of Austrian dividend payers (3.8%). In line with average of industry peers (6.3%). Declared Dividend • Apr 13
Dividend of €3.64 announced Shareholders will receive a dividend of €3.64. Ex-date: 19th May 2026 Payment date: 21st May 2026 Dividend yield will be 4.2%, which is about the same as the industry average. Board Change • Apr 08
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Ann Caluwaerts was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Mar 23
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Ann Caluwaerts was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Mar 10
Cofinimmo SA(ENXTBR:COFB) dropped from Brussels BEL 20 Index Cofinimmo SA removed Board Change • Mar 03
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Ann Caluwaerts was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Jan 07
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Ann Caluwaerts was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Jun 20
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Ann Caluwaerts was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Declared Dividend • May 19
Dividend of €4.34 announced Shareholders will receive a dividend of €4.34. Ex-date: 20th May 2025 Payment date: 22nd May 2025 Dividend yield will be 5.5%, which is higher than the industry average of 4.3%. Announcement • May 15
Cofinimmo SA announces Annual dividend, payable on May 22, 2025 Cofinimmo SA announced Annual dividend of EUR 4.3400 per share payable on May 22, 2025, ex-date on May 20, 2025 and record date on May 21, 2025. Reported Earnings • Apr 29
First quarter 2025 earnings released: EPS: €1.69 (vs €0.48 in 1Q 2024) First quarter 2025 results: EPS: €1.69 (up from €0.48 in 1Q 2024). Revenue: €86.8m (flat on 1Q 2024). Net income: €64.3m (up 268% from 1Q 2024). Profit margin: 74% (up from 20% in 1Q 2024). Revenue is forecast to decline by 2.3% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to remain flat. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Reported Earnings • Oct 27
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: €85.3m (down 5.3% from 3Q 2023). Net loss: €274.0k (down 102% from profit in 3Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 2.6% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 43 percentage points per year, which is a significant difference in performance. Reported Earnings • Jul 28
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: €87.9m (down 2.5% from 2Q 2023). Net income: €24.6m (up 155% from 2Q 2023). Profit margin: 28% (up from 11% in 2Q 2023). Revenue is expected to decline by 1.6% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 1.9%. New Risk • Jul 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (8.5% operating cash flow to total debt). Minor Risks Dividend is not well covered by cash flows (104% cash payout ratio). Share price has been volatile over the past 3 months (4.1% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding). Declared Dividend • May 11
Dividend of €4.34 announced Shareholders will receive a dividend of €4.34. Ex-date: 13th May 2024 Payment date: 3rd June 2024 Dividend yield will be 6.6%, which is higher than the industry average of 4.3%. Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: €0.48 (vs €0.53 in 1Q 2023) First quarter 2024 results: EPS: €0.48 (down from €0.53 in 1Q 2023). Revenue: €87.0m (up 2.4% from 1Q 2023). Net income: €17.5m (flat on 1Q 2023). Profit margin: 20% (in line with 1Q 2023). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 2.0%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 08
Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022) Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €389.0m (up 5.8% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 2.0%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Reported Earnings • Feb 26
Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022) Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €349.0m (down 5.1% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Buying Opportunity • Jan 18
Now 22% undervalued Over the last 90 days, the stock is up 24%. The fair value is estimated to be €88.59, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 0.9% per annum. Earnings is also forecast to grow by 48% per annum over the same time period. Buying Opportunity • Dec 30
Now 21% undervalued Over the last 90 days, the stock is up 12%. The fair value is estimated to be €90.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 0.5% per annum. Earnings is also forecast to grow by 47% per annum over the same time period. New Risk • Oct 28
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 72% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.5% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (6.8% average weekly change). Minor Risks Dividend is not well covered by cash flows (102% cash payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (13% net profit margin). Shareholders have been diluted in the past year (14% increase in shares outstanding). Reported Earnings • Oct 28
Third quarter 2023 earnings released: EPS: €0.34 (vs €4.60 in 3Q 2022) Third quarter 2023 results: EPS: €0.34 (down from €4.60 in 3Q 2022). Revenue: €83.1m (up 5.9% from 3Q 2022). Net income: €11.4m (down 92% from 3Q 2022). Profit margin: 14% (down from 189% in 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Announcement • Oct 07
Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million. Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 2,785,805
Price\Range: €60
Transaction Features: Rule 144A Announcement • Sep 27
An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million. An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million on September 25, 2023. New Risk • Jul 31
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 49% Last year net profit margin: 137% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.5% operating cash flow to total debt). Shares are highly illiquid. Minor Risks Profit margins are more than 30% lower than last year (49% net profit margin). Shareholders have been diluted in the past year (5.4% increase in shares outstanding). Reported Earnings • Jul 30
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: €85.3m (up 1.2% from 2Q 2022). Net income: €9.64m (down 94% from 2Q 2022). Profit margin: 11% (down from 187% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. New Risk • Jul 29
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 101% Dividend yield: 8.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.2% operating cash flow to total debt). Shares are highly illiquid. Minor Risks Dividend is not well covered by cash flows (101% cash payout ratio). Large one-off items impacting financial results. Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Announcement • Jul 14
Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home for € 7.35 million. Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home on for €7.35 million July 13, 2023.Cofinimmo SA (ENXTBR:COFB) completed the acquisition of The Park Nursing Home on July 13, 2023. Buying Opportunity • May 24
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 12%. The fair value is estimated to be €95.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 0.4% per annum. Earnings is also forecast to grow by 4.9% per annum over the same time period. Upcoming Dividend • May 08
Upcoming dividend of €4.34 per share at 7.2% yield Eligible shareholders must have bought the stock before 15 May 2023. Payment date: 17 May 2023. Trailing yield: 7.2%. Within top quartile of Austrian dividend payers (5.5%). Higher than average of industry peers (6.2%). Reported Earnings • Apr 30
First quarter 2023 earnings released: EPS: €0.53 (vs €5.28 in 1Q 2022) First quarter 2023 results: EPS: €0.53 (down from €5.28 in 1Q 2022). Revenue: €84.6m (up 5.8% from 1Q 2022). Net income: €17.5m (down 90% from 1Q 2022). Profit margin: 21% (down from 209% in 1Q 2022). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 22
Full year 2022 earnings released: EPS: €15.09 (vs €8.78 in FY 2021) Full year 2022 results: EPS: €15.09 (up from €8.78 in FY 2021). Revenue: €325.1m (down 5.2% from FY 2021). Net income: €482.9m (up 86% from FY 2021). Net asset value (NAV) per share: €118 (flat on FY 2021). The current share price is 27% lower than NAV per share. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 30
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: €76.6m (up 6.2% from 3Q 2021). Net income: €148.3m (up 103% from 3Q 2021). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the REITs industry in Europe. Announcement • Oct 21
Cofinimmo SA acquired Four nursing homes in Germany. Cofinimmo SA acquired Four nursing homes in Germany on October 20, 2022. Fabian BÃhm of Clifford Chance Partnerschaftsgesellschaft acted as legal advisor to Cofinimmo SA.
Cofinimmo SA completed the acquisition of Four nursing homes in Germany on October 20, 2022. Announcement • Oct 20
Cofinimmo SA (ENXTBR:COFB) signed agreement to acquire Four Nursing And Care Homes In Germany for €61 million. Cofinimmo SA (ENXTBR:COFB) signed agreement to acquire Four Nursing And Care Homes In Germany for €61 million on October 18, 2022. Announcement • Oct 06
Cofinimmo SA (ENXTBR:COFB) acquired Nursing And Care Home In Netherlands for approximately €12 million. Cofinimmo SA (ENXTBR:COFB) acquired Nursing And Care Home In Netherlands for approximately €12 million on October 5, 2022.
Cofinimmo SA (ENXTBR:COFB) completed the acquisition of Nursing And Care Home In Netherlands on October 5, 2022. Reported Earnings • Jul 29
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: €79.4m (up 7.6% from 2Q 2021). Net income: €157.6m (up 213% from 2Q 2021). Over the next year, revenue is expected to shrink by 3.0% compared to a 2.1% growth forecast for the industry in Austria. Announcement • Jul 28
Cofinimmo SA (ENXTBR:COFB) acquired Medical office building in Vlaardingen for €5 million. Cofinimmo SA (ENXTBR:COFB) acquired Medical office building in Vlaardingen for €5 million on July 27, 2022.
Cofinimmo SA (ENXTBR:COFB) completed the acquisition of Medical office building in Vlaardingen on July 27, 2022. Board Change • Jun 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Michael Zahn was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • May 09
Upcoming dividend of €4.20 per share Eligible shareholders must have bought the stock before 16 May 2022. Payment date: 18 May 2022. Trailing yield: 4.9%. Within top quartile of Austrian dividend payers (4.4%). Higher than average of industry peers (4.4%). Reported Earnings • May 01
First quarter 2022 earnings released First quarter 2022 results: Revenue: €79.2m (up 12% from 1Q 2021). Net income: €167.0m (up 271% from 1Q 2021). Over the next year, revenue is forecast to decline by 4.3% while the industry in Austria is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 4% per year. Board Change • Apr 28
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 10
Full year 2021 earnings released: EPS: €8.77 (vs €4.50 in FY 2020) Full year 2021 results: EPS: €8.77 (up from €4.50 in FY 2020). Revenue: €302.0m (up 3.2% from FY 2020). Net income: €260.0m (up 118% from FY 2020). Profit margin: 86% (up from 41% in FY 2020). The increase in margin was primarily driven by lower expenses. Over the next year, revenue is forecast to grow 8.6% while the reits industry in Austria is not expected to grow. Over the last 3 years on average, earnings per share has increased by 4% per year and the company’s share price has also increased by 4% per year. Reported Earnings • Feb 25
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: €8.22 (up from €4.50 in FY 2020). Revenue: €299.6m (up 2.3% from FY 2020). Net income: €260.3m (up 118% from FY 2020). Profit margin: 87% (up from 41% in FY 2020). Revenue missed analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 12% while thereits industry in Austria is not expected to grow. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 2% per year. Announcement • Dec 22
Cofinimmo SA (ENXTBR:COFB) acquired Nursing and care home in Charleroi for €18 million. Cofinimmo SA (ENXTBR:COFB) acquired Nursing and care home in Charleroi for €18 million on December 21, 2021. The conventional value of the site for the calculation of the share price amounts to approximately €18 million.
Cofinimmo SA (ENXTBR:COFB) completed the acquisition of Nursing and care home in Charleroi on December 21, 2021. Announcement • Nov 30
Cofinimmo SA (ENXTBR:COFB) acquired Nursing and Care Home in Chanteloup-les-Vignes. Cofinimmo SA (ENXTBR:COFB) acquired Nursing and Care Home in Chanteloup-les-Vignes on November 30, 2021. The conventional value of the asset for the calculation of the share price amounts to approximately €17 million.
Cofinimmo SA (ENXTBR:COFB) completed the acquisition of Nursing and Care Home in Chanteloup-les-Vignes on November 30, 2021. Announcement • Nov 24
Cofinimmo SA (ENXTBR:COFB) agreed to acquire three nursing and care homes in Germany for €39 million. Cofinimmo SA (ENXTBR:COFB) agreed to acquire three nursing and care homes in Germany for €39 million on November 22, 2021. The consideration price of €39 million includes real estate transfer taxes and will be paid upon lifting of conditions (primarily administrative) in the first quarter of 2022. Reported Earnings • Oct 29
Third quarter 2021 earnings released: EPS €2.44 (vs €1.45 in 3Q 2020) Third quarter 2021 results: Revenue: €72.6m (up 123% from 3Q 2020). Net income: €73.1m (up 87% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Announcement • Sep 07
Cofinimmo SA (ENXTBR:COFB) acquired Nursing and Care Home in Fontainebleau, South-east of Paris from Promoval Partenaires. Cofinimmo SA (ENXTBR:COFB) acquired Nursing and Care Home in Fontainebleau, South-east of Paris from Promoval Partenaires on September 6, 2021. The investment budget for the building and the works amounts to approximately €17 million.
Cofinimmo SA (ENXTBR:COFB) completed the acquisition of Nursing and Care Home in Fontainebleau, South-east of Paris from Promoval Partenaires on September 6, 2021. Announcement • Jul 27
Cofinimmo SA (ENXTBR:COFB) acquired Three recent nursing and care homes in England for approximately £57 million. Cofinimmo SA (ENXTBR:COFB) acquired Three recent nursing and care homes in England for approximately £57 million on July 26, 2021. The portfolio represent 196 beds and a total surface area of approximately 9,500 square meter. The sites are fully leased to Country Court Care Group Limited and consist of Ferrars Hall, Lakeview Lodge and Oakview Lodge.
Cofinimmo SA (ENXTBR:COFB) completed the acquisition of Three recent nursing and care homes in England on July 26, 2021. Announcement • Jul 16
Cofinimmo SA (ENXTBR:COFB) acquired New nursing and care home in Bilbao, Spain for €9 million. Cofinimmo SA (ENXTBR:COFB) acquired New nursing and care home in Bilbao, Spain for €9 million on July 15, 2021.
Cofinimmo SA (ENXTBR:COFB) completed the acquisition of New nursing and care home in Bilbao, Spain on July 15, 2021. Announcement • Jul 03
Cofinimmo SA (ENXTBR:COFB) acquired 95% stake in Celenus Klinik an der Salza. Cofinimmo SA (ENXTBR:COFB) acquired 95% stake in Celenus Klinik an der Salza on July 1, 2021. The conventional value of the asset for the calculation of the share price amounts to approximately €22 million.
Cofinimmo SA (ENXTBR:COFB) completed the acquisition of 95% stake in Celenus Klinik an der Salza on July 1, 2021. Announcement • Jun 01
Brody Projectontwikkeling & Investeringen acquired office buildings located in Antwerp and Brussels from Cofinimmo SA (ENXTBR:COFB) for approximately €80 million. Brody Projectontwikkeling & Investeringen acquired office buildings located in Antwerp and Brussels from Cofinimmo SA (ENXTBR:COFB) for approximately €80 million on May 31, 2021.
Brody Projectontwikkeling & Investeringen completed the acquisition of office buildings located in Antwerp and Brussels from Cofinimmo SA (ENXTBR:COFB) on May 31, 2021. Announcement • May 13
Cofinimmo SA (ENXTBR:COFB) signed an agreement to acquire Nursing and Care Home in Leipzig, Germany for approximately €19 million. Cofinimmo SA (ENXTBR:COFB) signed an agreement to acquire Nursing and Care Home in Leipzig, Germany for approximately €19 million on May 11, 2021. The nursing and care home is currently under construction in Leipzig and is already pre-let to AZURIT Rohr GmbH, which is part of the AZURIT Group, one of the leading operators in Germany. Closing is expected to take place in the first quarter of 2022. Upcoming Dividend • May 11
Upcoming dividend of €4.06 per share Eligible shareholders must have bought the stock before 17 May 2021. Payment date: 19 May 2021. Trailing yield: 4.6%. Within top quartile of Austrian dividend payers (3.2%). Higher than average of industry peers (3.6%). Reported Earnings • May 02
First quarter 2021 earnings released: EPS €1.67 (vs €1.64 in 1Q 2020) The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €71.0m (down 20% from 1Q 2020). Net income: €45.1m (up 6.9% from 1Q 2020). Profit margin: 64% (up from 48% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Reported Earnings • Apr 11
Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €259.2m (down 9.2% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 46% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Reported Earnings • Feb 28
Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €259.2m (down 9.2% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 46% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Feb 28
Revenue beats expectations Revenue exceeded analyst estimates by 3.3%. Over the next year, revenue is expected to shrink by 1.1% compared to a 3.9% growth forecast for the REITs industry in Austria. Announcement • Feb 27
Cofinimmo SA to Report Q3, 2021 Results on Oct 27, 2021 Cofinimmo SA announced that they will report Q3, 2021 results at 3:40 PM, Coordinated Universal Time on Oct 27, 2021 Is New 90 Day High Low • Feb 06
New 90-day high: €130 The company is up 5.0% from its price of €123 on 06 November 2020. The Austrian market is up 38% over the last 90 days, indicating the company underperformed over that time. It also underperformed the REITs industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €153 per share. Announcement • Jan 23
Cofinimmo SA (ENXTBR:COFB) acquired a nursing and care Home Under Construction in Vantaa from Fincap KiinteistOkehitys Oy for €12 million. Cofinimmo SA (ENXTBR:COFB) acquired a nursing and care Home Under Construction in Vantaa from Fincap KiinteistOkehitys Oy for €12 million on January 21, 2021. The total investment budget for the plot of land and the works amounts to approximately €12 million.
Cofinimmo SA (ENXTBR:COFB) completed the acquisition of a nursing and care Home Under Construction in Vantaa from Fincap KiinteistOkehitys Oy on January 21, 2021. Catella Property Oy acted as financial advisor to Fincap KiinteistOkehitys Oy. Announcement • Jan 20
Cofinimmo SA (ENXTBR:COFB) acquired Six nursing and care homes and one rehabilitation clinic in Ireland for €93 million. Cofinimmo SA (ENXTBR:COFB) acquired Six nursing and care homes and one rehabilitation clinic in Ireland for €93 million on January 18, 2021. All sites are let to DomusVi.
Cofinimmo SA (ENXTBR:COFB) completed the acquisition of Six nursing and care homes and one rehabilitation clinic in Ireland on January 18, 2021. Reported Earnings • Jan 16
Third quarter 2020 earnings released: EPS €1.45 Third quarter 2020 results: Revenue: €32.5m (up 9.0% from 3Q 2019). Net income: €39.2m (down 37% from 3Q 2019). Announcement • Dec 17
Cofinimmo SA (ENXTBR:COFB) acquired a new nursing and care home in Castellón de la Plana, Spain for €9 million. Cofinimmo SA (ENXTBR:COFB) acquired a new nursing and care home in Castellón de la Plana, Spain for €9 million on December 15, 2020.
Cofinimmo SA (ENXTBR:COFB) completed the acquisition of a new nursing and care home in Castellón de la Plana, Spain on December 15, 2020. Reported Earnings • Nov 21
Third quarter 2020 earnings released: EPS €1.45 Third quarter 2020 results: Revenue: €32.5m (down 52% from 3Q 2019). Net income: €39.2m (down 37% from 3Q 2019). Announcement • Nov 20
Cofinimmo SA to Report First Half, 2021 Results on Jul 28, 2021 Cofinimmo SA announced that they will report first half, 2021 results on Jul 28, 2021 Announcement • Nov 06
Cofinimmo SA (ENXTBR:COFB) agreed to acquire Two Nursing and Care Homes in The Land of Lower Saxony. Cofinimmo SA (ENXTBR:COFB) agreed to acquire Two Nursing and Care Homes in The Land of Lower Saxony on November 4, 2020. The transaction includes Seniorenheim am Rosentor in Aurich and Seniorenresidenz Josefinenhof in Wiesmoor. The transaction is subject to certain conditions. Is New 90 Day High Low • Oct 29
New 90-day low: €116 The company is down 2.0% from its price of €119 on 30 July 2020. The Austrian market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the REITs industry, which is down 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €133 per share.